| Oct 9 |
Coherus BioSciences Inc (CHRS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...
|
| Sep 28 |
Coherus BioSciences, Inc. (CHRS): Worst 52-Week Low Stock to Buy Now
|
| Sep 25 |
Short Interest Surges to 21.83% as Coherus BioSciences, Inc. (CHRS) Faces Revenue Challenges
|
| Sep 20 |
Institutional owners may take dramatic actions as Coherus BioSciences, Inc.'s (NASDAQ:CHRS) recent 12% drop adds to one-year losses
|
| Aug 16 |
UBS cuts Coherus to neutral, cites limited growth opportunities
|
| Aug 13 |
Evaluating Coherus BioSciences: Udenyca's Success And Loqtorzi's Prospects
|
| Aug 10 |
Coherus BioSciences Second Quarter 2024 Earnings: Beats Expectations
|
| Aug 9 |
Coherus BioSciences, Inc. (CHRS) Q2 2024 Earnings Call Transcript
|
| Aug 8 |
Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 8 |
Coherus BioSciences: Q2 Earnings Snapshot
|
